Advances in the prevention and treatment of lung cancer

Journal of the Royal College of Physicians of Edinburgh

Volumn 41, Issue 2, 2011, Pages 142-149

  Hodkinson, P S ^a   Sethi, T ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Biological therapy; Genetics; Inflammation; Lung cancer; Screening; Smoking

Indexed keywords

AMFEBUTAMONE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLACEBO; VARENICLINE; VASCULOTROPIN;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CHROMOSOME 15Q; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME 6Q; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; COUNSELING; DRUG RESPONSE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LUNG CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; NICOTINE REPLACEMENT THERAPY; PNEUMONIA; REVIEW; RISK REDUCTION; SMOKING CESSATION; THORAX RADIOGRAPHY; TOBACCO DEPENDENCE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; EARLY DETECTION OF CANCER; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; NEOPLASM STAGING; PNEUMONIA; RISK FACTORS; SMOKING;

EID: 80052719453     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2011.219     Document Type: Review

References (110)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92. doi:10.1093/annonc/mdl498
2. Harkness EF, Brewster DH, Kerr KM et al. Changing trends in incidence of lung cancer by histologic type in Scotland. Int J Cancer 2002; 102:179-83. doi:10.1002/ijc.10661
3. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003; 41:245-58. doi:10.1016/ S0169-5002(03)00230-7
4. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007; 45:21-43. doi:10.1016/j.rcl.2006.10.004
5. Ettinger DS. Overview and state of the art in the management of lung cancer. Oncology 2004; 18:3-9.
6. Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest 2003; 123:181-7. doi:10.1378/chest.123.1_suppl.181S
7. Molina JR, Yang P, Cassivi SD et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-94. doi:10.4065/83.5.584
8. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950; 2:739-48. doi:10.1136/bmj.2.4682.739
9. Crispo A, Brennan P, Jöckel KH et al. The cumulative risk of lung cancer among current, ex-and never-smokers in European men. Br J Cancer 2004; 91:1280-6. doi:10.1038/sj.bjc.6602078
10. Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health 1978; 32:303-13. doi:10.1136/jech.32.4.303
11. Tulunay OE, Hecht SS, Carmella SG et al. Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev 2005; 14:1283-6. doi:10.1158/1055-9965.EPI-04-0570
12. Samet JM, Avila-Tong E, Boffetta P et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 2009; 15:5626-45. doi:10.1158/1078-0432.CCR-09-0376
13. Shibuya K, Inoue M and Lopez AD. Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int J Cancer 2005; 117:476-85. doi:10.1002/ijc.21078
14. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44:1345-89. doi:10.1016/j.ejca.2007.12.015
15. Ebbert JO, Yang P, Vachon CM et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003; 21:921-6. doi:10.1200/JCO.2003.05.085
16. Peto R, Darby S, Deo H et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323-9. doi:10.1136/ bmj.321.7257.323
17. Parsons A, Daley A, Begh R et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340:251. doi:10.1136/bmj.b5569
18. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362:2295-303. doi:10.1056/NEJMra0809890
19. Doggrell SA. Partial agonism at nicotinic receptors with varenicline-a new approach to smoking cessation. Expert Opin Pharmacother 2006; 7:2599-603. doi:10.1517/14656566.7.18.2599
20. Gonzales D, Rennard SI, Nides M et al. Varenicline, an a4b2 nicotine acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation-a randomized controlled trial. JAMA 2006; 296:47-55. doi:10.1001/jama.296.1.47
21. Tonstad S, Tennesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation-a randomized controlled trial. JAMA 2006; 296:64-71. doi:10.1001/jama.296.1.64
22. Kanner RE, Connett JE, Williams DE et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999; 106:410-6. doi:10.1016/S0002-9343(99)00056-X
23. Bierut LJ. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends Pharmacol Sci 2010; 31:46-51. doi:10.1016/j.tips.2009.10.004
24. Wakelee HA, Chang ET, Gomez SL et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472-8. doi:10.1200/ JCO.2006.07.2983
25. Coté ML, Kardia SL, Wenzlaff AS et al. Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 2005; 293:3036-42. doi:10.1001/jama.293.24.3036
26. Bailey-Wilson JE, Amos CI, Pinney SM et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004; 75:460-74. doi:10.1086/423857
27. You M, Wang D, Liu P et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 2009; 15:2666-74. doi:10.1158/1078-0432.CCR-08-2335
28. Wang Y, Broderick P, Webb E et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40:1407-9. doi:10.1038/ng.273
29. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifi es a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40:616-22. doi:10.1038/ng.109
30. Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633-7. doi:10.1038/nature06885
31. Brennan P, Hainaut P and Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol 2011; 12:399-408. doi:10.1016/S1470-2045(10)70126-1
32. Pleasance ED, Stephens PJ, O'Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463:184-90. doi:10.1038/nature08629
33. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465:473-7. doi:10.1038/nature09004
34. Humphrey LL, Teutsch S, Johnson M et al. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:740-53.
35. Nawa T, Nakagawa T, Kusano S et al. Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest 2002; 122:15-20. doi:10.1378/chest.122.1.15
36. Sone S, Li F, Yang ZG, Honda T et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84:25-32. doi:10.1054/bjoc.2000.1531
37. Henschke CI, Yankelevitz DF, Libby DM et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci 2001; 952:124-34. doi:10.1111/j.1749-6632.2001.tb02733.x
38. Swensen SJ, Jett JR, Sloan JA et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002; 165:508-13.
39. Aberle DR, Berg CD, Black WC et al. The National Lung Screening Trial: overview and study design. Radiology 2011; 258:243-53. doi:10.1148/radiol.10091808
40. Pedersen JH, Ashraf H, Dirksen A et al. The Danish randomized lung cancer CT screening trial-overall design and results of the prevalence round. J Thorac Oncol 2009; 4:608-14. doi:10.1097/ JTO.0b013e3181a0d98f
41. Lopes Pegna A, Picozzi G, Mascalchi M et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009; 64:34-40. doi:10.1016/j.lungcan.2008.07.003
42. Montes U, Seijo LM, Campo A et al. Factors determining early adherence to a lung cancer screening protocol. Eur Respir J 2007; 30:532-7. doi:10.1183/09031936.00143206
43. MacMahon H, Austin JHM, Gamsu G et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237:395-400. doi:10.1148/radiol.2372041887
44. Cronin P, Dwamena BA, Kelly AM et al. Solitary Pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008; 246:772-82. doi:10.1148/radiol.2463062148
45. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol 2010; 37:202-15. doi:10.1053/j.seminoncol.2010.05.006
46. Baldwin DR, Duffy SW, Wald NJ et al. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011; 66:308-13. doi:10.1136/thx.2010.152066
47. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009; 136:260-71. doi:10.1378/chest.08-0978
48. Ravenel JG, Mohammed TL, Movsas B et al. ACR Appropriateness Criteria® noninvasive clinical staging of bronchogenic carcinoma. J Thorac Imaging 2010; 25:W107-11. doi:10.1097/ RTI.0b013e3181f51e7f
49. Rintoul RC, Skwarski KM, Murchison JT et al. Endobronchial and endoscopic ultrasound-guided real-time fine-needle aspiration for mediastinal staging. Eur Respir J 2005; 25:416-21. doi:10.1183/09031936.05.00095404
50. Annema JT, van Meerbeeck JP, Rintoul RC et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA 2010; 304:2245-52. doi:10.1001/ jama.2010.1705
51. Lawson MH, Rassl DM, Cummings NM et al. Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA. J Thorac Oncol 2010; 5:956-63.
52. Smolle-Juettner FM, Maier A, Lindenmann J et al. Resection in stage I/II non-small cell lung cancer. Front Radiat Ther Oncol 2010; 42:71-7. doi:10.1159/000262462
53. Jeremic B, Casas F, Wang L, et al. Radiation therapy for early stage (I/II) non-small cell lung cancer. Front Radiat Ther Oncol 2010; 42:87-93. doi:10.1159/000262464
54. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-9. doi:10.1200/JCO.2007.13.9030
55. Mayor S. NICE issues guidance for diagnosis and treatment of lung cancer. BMJ 2005; 330:439. doi:10.1136/bmj.330.7489.439-b
56. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2005; 2:CD002142.
57. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24:2998-3006. doi:10.1200/JCO.2005.04.6110
58. Sawyer TE, Bonner JA, Gould PM et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997; 80:1399-408. doi:10.1002/(SICI)1097-0142(19971015)80:8<1399::AID-CNCR6>3.0.CO;2-A
59. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011; epub ahead of print Mar 4.
60. Emami B, Kaiser L, Simpson J et al. Postoperative radiation therapy in non-small cell lung cancer. Am J Clin Oncol 1997; 20:441-8. doi:10.1097/00000421-199710000-00003
61. The Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988; 6:9-17.
62. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000; 2:CD002139.
63. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000; 343:1217-22. doi:10.1056/NEJM200010263431703
64. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
65. O'Rourke N, Roquéi Figuls M, Farré Bernadó N et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010; 6:CD002140.
66. Kim TE, Murren JR. Therapy for stage IIIB and stage IV non-small cell lung cancer. Clin Chest Med 2002; 23:209-24. doi:10.1016/S0272-5231(03)00069-8
67. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced nonsmall-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26:4617-25. doi:10.1200/JCO.2008.17.7162
68. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-51. doi:10.1200/ JCO.2007.15.0375
69. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. J Clin Oncol 2000; 18:2354-62.
70. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43:183-94. doi:10.1016/j.lungcan.2003.09.001
71. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-97. doi:10.1200/JCO.2004.08.163
72. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-98. doi:10.1200/JCO.2008.17.1405
73. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-40. doi:10.1016/S0140-6736(09)61497-5
74. Hodkinson PS, Mackinnon A, Sethi T. Targeting growth factors in lung cancer. Chest 2008; 133:1209-16. doi:10.1378/chest.07-2680
75. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7:251-65. doi:10.1038/nrclinonc.2010.41
76. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-70.
77. Meert AP, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with metaanalysis. Eur Respir J 2002; 20:975-81. doi:10.1183/09031936.02.00296502
78. Ettinger DS. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 2010; 68:332-7. doi:10.1016/j.lungcan.2009.07.012
79. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-31. doi:10.1016/S0140-6736(09)60569-9
80. Ibrahim EM, Abouelkhair KM, Al-Masri OA et al. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Lung 2011; epub ahead of print Mar 20.
81. Joerger M, Matter-Walstra K, Früh M et al. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2011; 22:567-74. doi:10.1093/annonc/mdq431
82. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237-46. doi:10.1200/JCO.2003.10.038
83. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58. doi:10.1001/ jama.290.16.2149
84. Crinò L, Cappuzzo F, Zatloukal P et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-smallcell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008; 26:4253-60. doi:10.1200/JCO.2007.15.0672
85. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37. doi:10.1016/S0140-6736(05)67625-8
86. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-94. doi:10.1200/JCO.2004.07.215
87. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-84. doi:10.1200/JCO.2004.08.001
88. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-18. doi:10.1016/ S0140-6736(08)61758-4
89. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32. doi:10.1056/NEJMoa050753
90. Haas-Kogan DA, Prados MD, Lamborn KR et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005; 4:1369-72. doi:10.4161/cc.4.10.2105
91. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500. doi:10.1126/science.1099314
92. Pircher A, Ploner F, Popper H et al. Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer 2010; 69:265-71. doi:10.1016/j.lungcan.2010.01.017
93. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57. doi:10.1056/NEJMoa0810699
94. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011; epub ahead of print Feb 28.
95. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401-10. doi:10.1038/nrc1093
96. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51:143-58. doi:10.1016/j.lungcan.2005.09.005
97. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:1227-34. doi:10.1200/JCO.2007.14.5466
98. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. doi:10.1056/NEJMoa061884
99. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-5. doi:10.1200/JCO.2007.13.1144
100. Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic nonsmall cell lung cancer. J Thoracic Oncol 2008; 3(Suppl 2):S128-30. doi:10.1097/JTO.0b013e318174e95a
101. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009; 15:303-7. doi:10.1097/MCP.0b013e32832c975a
102. Kiri VA, Fabbri LM, Davis KJ et al. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med 2009; 103:85-90. doi:10.1016/j.rmed.2008.07.024
103. Yu YY, Pinsky PF, Caporaso NE et al. Lung cancer risk following detection of pulmonary scarring by chest radiography in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Arch Intern Med 2008; 168:2326-32. doi:10.1001/archinte.168.21.2326
104. Chaturvedi AK, Caporaso NE, Katki HA et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010; 28:2719-26. doi:10.1200/ JCO.2009.27.0454
105. Moghaddam SJ, Li H, Cho SN et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009; 40:443-53. doi:10.1165/rcmb.2008-0198OC
106. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med 2008; 14:1023-4. doi:10.1038/ nm1008-1023
107. Takahashi H, Ogata H, Nishigaki R et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKb and JNK1 dependent inflammation. Cancer Cell 2010; 17:89. doi:10.1016/j. ccr.2009.12.008
108. Bremnes RM, Al-Shibli K, Donnem T et al. The role of tumorinfiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2010; epub ahead of print Dec 17.
109. Dai F, Liu L, Che G et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010; 10:220. doi:10.1186/1471-2407-10-220
110. Rauh MJ, Ho V, Pereira C et al. SHIP represses the generation of alternatively activated macrophages. Immunity 2005; 23:361-74. doi:10.1016/j.immuni.2005.09.003